First-time AOM semaglutide prescribing increased by over 50%, marking the largest quarter-over-quarter increase in first-time AOM semaglutide prescribing since mid-2024, likely driven by the approval of the oral formulation of Wegovy in December 2025
For insights professionals at leading retailers, understanding these emerging consumer segments is essential to capturing market growth and brand loyalty
GHK-Cu also shows cytoprotective effects in the gastrointestinal tract
IV Therapy Rehydrate, fight off fatigue, conquer jet lag, strengthen immunity, sharpen mental clarity, restore your skins natural radiance, and much more
Some people anecdotally report more digestive side effects with tirzepatide compared to semaglutide, potentially including sulfur burps, though systematic data is limited
2020JH2/10300050) to this article